Clinical trial • Phase I • Immunology
SAR447754 for Atopic dermatitis
Phase I trial of SAR447754 for Atopic dermatitis. 207 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Atopic dermatitis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 04-12-2025
- First CTIS Authorization Date
- 16-02-2026
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 207
- Trial Duration For Participant
- 824
Eligibility
Recruits 207 Vulnerable population selected; no details on consent or assent provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 207
- Recruitment Window Months
- 27
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 207
Belgium
- Earliest CTIS Part Ii Submission Date
- 02-02-2026
- Latest Decision Or Authorization Date
- 09-04-2026
- Processing Time Days
- 66
- Number Of Sites
- 1
- Number Of Participants
- 207
Sites
- Site Name
- SGS Belgium - Drie Eikenstraat 655
- Department Name
- SGS Clinical Research, Clinical Pharmacology Unit
- Contact Person Name
- Lotte Verwilligen
- Contact Person Email
- lotte.verwilligen@sgs.com
Sponsor
Primary sponsor
- Full Name
- Sanofi-Aventis Recherche & Developpement
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- SAR447754
- First In Human
- Yes
Related trials
Other published trials that may interest you.